174 related articles for article (PubMed ID: 25869098)
21. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.
Yan W; Zhang W; You G; Bao Z; Wang Y; Liu Y; Kang C; You Y; Wang L; Jiang T
PLoS One; 2012; 7(1):e30339. PubMed ID: 22291938
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
Wong ST; Zhang XQ; Zhuang JT; Chan HL; Li CH; Leung GK
Anticancer Res; 2012 Jul; 32(7):2835-41. PubMed ID: 22753745
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
Zhang S; Wan Y; Pan T; Gu X; Qian C; Sun G; Sun L; Xiang Y; Wang Z; Shi L
J Mol Neurosci; 2012 Jun; 47(2):346-56. PubMed ID: 22528454
[TBL] [Abstract][Full Text] [Related]
24. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
[TBL] [Abstract][Full Text] [Related]
26. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
27. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G
Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996
[TBL] [Abstract][Full Text] [Related]
28. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
29. miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.
Ujifuku K; Mitsutake N; Takakura S; Matsuse M; Saenko V; Suzuki K; Hayashi K; Matsuo T; Kamada K; Nagata I; Yamashita S
Cancer Lett; 2010 Oct; 296(2):241-8. PubMed ID: 20444541
[TBL] [Abstract][Full Text] [Related]
30. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
31. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
32. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Wu Y; Yao Y; Yun Y; Wang M; Zhu R
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31409725
[TBL] [Abstract][Full Text] [Related]
34. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Wang HW; Xu ZK; Song Y; Liu YG
Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
[TBL] [Abstract][Full Text] [Related]
35. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
[TBL] [Abstract][Full Text] [Related]
36. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
[TBL] [Abstract][Full Text] [Related]
37. RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).
Xu J; Song J; Xiao M; Wang C; Zhang Q; Yuan X; Tian S
Bioengineered; 2021 Dec; 12(2):11768-11781. PubMed ID: 34895074
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
39. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
40. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]